News
PCVX
55.26
-0.43%
-0.24
Weekly Report: what happened at PCVX last week (0720-0724)?
Weekly Report · 1d ago
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
Seeking Alpha · 3d ago
Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential
Seeking Alpha · 6d ago
Weekly Report: what happened at PCVX last week (0713-0717)?
Weekly Report · 07/20 09:17
Vaxcyte files Form 3 initial beneficial ownership statement for director John Markels
PUBT · 07/16 20:56
Vaxcyte names John Markels to board as Heath Lukatch retires
PUBT · 07/15 20:07
Guggenheim Reaffirms Their Buy Rating on Vaxcyte (PCVX)
TipRanks · 07/14 11:16
Weekly Report: what happened at PCVX last week (0706-0710)?
Weekly Report · 07/13 09:17
Vaxcyte to Participate in Upcoming Investor Conferences
Barchart · 07/08 15:05
Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors?
Simply Wall St · 07/07 07:32
Vaxcyte COO Jim Wassil sells 2,250 common shares for $127,708.38
PUBT · 07/06 22:26
Weekly Report: what happened at PCVX last week (0629-0703)?
Weekly Report · 07/06 09:18
Vaxcyte (PCVX) Updates VAX A1 Trial, Is It Still A Bargain?
Simply Wall St · 07/04 14:30
Have Insiders Sold Vaxcyte Shares Recently?
Simply Wall St · 07/02 14:48
Weekly Report: what happened at PCVX last week (0622-0626)?
Weekly Report · 06/29 09:17
Is Vaxcyte’s (PCVX) Russell Index Debut Quietly Reframing Its Long‑Term Governance And Growth Story?
Simply Wall St · 06/29 01:13
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Vaxcyte (PCVX)
TipRanks · 06/26 11:00
Vaxcyte Announces Board Transition and New Director Appointment
TipRanks · 06/23 20:32
Vaxcyte files initial beneficial ownership statement for director Moncef Slaoui
PUBT · 06/23 20:20
Vaxcyte names Moncef Slaoui to board after Jacks Lee retirement
PUBT · 06/23 20:10
More
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.